Nov 15, 2017   SOURCE: PR NewsWire

World Cancer Liquid Biopsy Market 2017 - Insufficient Demonstrated Clinical Utility to Slow Adoption by Oncologists

DUBLIN, November 15, 2017 /PRNewswire/ --

The "Cancer Liquid Biopsy Market Assessment" report has been added to Research and Markets' offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy contains markets for the following:

    --  Breast Cancer Liquid Biopsy Market
    --  Colorectal Cancer Liquid Biopsy Market

    --  Lung Cancer Liquid Biopsy Market

    --  Ovarian Cancer Liquid Biopsy Market
    --  Pancreatic Cancer Liquid Biopsy Market
    --  Other Cancer Liquid Biopsy Market

Top Ten Companies in the Market:

The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging.

Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it.

Circulating tumor cells (CTCs) are cancer cells that are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs, initiating the process of metastasis, and forming new tumors. Similarly to ctDNA, CTC-based tests could offer significant advantages compared to tissue biopsies, as they may be able to capture the heterogeneity of tumors and their genetic evolution during the disease progression and therapy.

Compared to ctDNA, CTCs have a longer half-life in blood, and the analysis of viable cells could provide information about protein expression, such as PD-L1 or ER, which is not possible with ctDNA. Also, since CTCs contain intact genomic material from tumors, their analysis can reveal additional information about the biology of cancer and metastasis that is not possible to obtain from ctDNA.

This report segments market by type of cancer and corresponding regional market.

Key Topics Covered:

1. Executive Summary

    --  Introduction
    --  Liquid Biopsy Technologies
    --  Industry Structure
    --  Liquid Biopsy Market Revenues And Forecast

2. Liquid Biopsy Technologies

    --  Introduction
    --  Current Major Liquid Biopsy Technologies
    --  Circulating Free DNA
    --  Advantages And Limitations Of Ctdna In Liquid Biopsy
    --  Current Ctdna-Based Liquid Biopsy Tests
    --  Adaptive Biotechnologies
    --  Biodesix
    --  Epigenomics
    --  Foundation Medicine
    --  Genomic Health
    --  Guardant Health
    --  Myriad Genetics
    --  Pathway Genomics
    --  Personal Genome Diagnostics
    --  QIAGEN
    --  Roche Diagnostics
    --  Sysmex-Inostics
    --  Trovagene
    --  Circulating Tumor Cells (Ctcs) Liquid Biopsy
    --  Challenges In The Development Of Ctcs-Based Liquid Biopsy Tests
    --  Ctcs-Based Liquid Biopsy Tests
    --  Biocept
    --  Cynvenio Biosystems
    --  Epic Sciences
    --  GILUPI
    --  Menarini-Silicon Biosystems
    --  QIAGEN
    --  Extracellular Vesicles And Other Liquid Biopsy
    --  Introduction
    --  Liquid Biopsy Tests Based On Extracellular Vesicles
    --  Biodesix
    --  Exosome Diagnostics
    --  Gensignia
    --  Hologic
    --  MDxHealth
    --  OncoCyte
    --  QIAGEN
    --  Vermillion
    --  VolitionRx

3. Liquid Biopsy Industry Analysis

    --  Introduction
    --  Tiers Of Competition
    --  Competitive Factors
    --  Significant Market Trends
    --  Personalized Medicine to Spur Use of Liquid Biopsy Tests in Clinical
        Practice
    --  Increasing Global Incidence of Cancer and Life Expectancy to Increase
        Testing Volumes
    --  New Liquid Biopsy Product Launches to Augment Market Revenues
    --  Decreasing Cost of Genetic Testing to Increase Utilization of Liquid
        Biopsy Tests
    --  Regulatory Hurdles to Limit Market Growth
    --  Limitations in Third-party Payer Coverage to Restrict Test Utilization
        and Market Growth
    --  Insufficient Demonstrated Clinical Utility to Slow Adoption by
        Oncologists
    --  Challenges in the Integration of Liquid Biopsy Tests in Clinical
        Practice to Limit Market Growth

4. Cancer Liquid Biopsy Market Analysis

For more information about this report visit https://www.researchandmarkets.com/research/23z4lg/cancer_liquid

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/world-cancer-liquid-biopsy-market-2017---insufficient-demonstrated-clinical-utility-to-slow-adoption-by-oncologists-300556700.html

SOURCE Research and Markets